Cargando…
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225943/ https://www.ncbi.nlm.nih.gov/pubmed/32325748 http://dx.doi.org/10.3390/cancers12041003 |
_version_ | 1783534171137769472 |
---|---|
author | Leeneman, Brenda Uyl-de Groot, Carin A. Aarts, Maureen J. B. van Akkooi, Alexander C. J. van den Berkmortel, Franchette W. P. J. van den Eertwegh, Alfons J. M. de Groot, Jan Willem B. Herbschleb, Karin H. van der Hoeven, Jacobus J. M. Hospers, Geke A. P. Kapiteijn, Ellen Piersma, Djura van Rijn, Rozemarijn S. Suijkerbuijk, Karijn P. M. ten Tije, Albert J. van der Veldt, Astrid A. M. Vreugdenhil, Gerard Wouters, Michel W. J. M. Haanen, John B. A. G. Franken, Margreet G. |
author_facet | Leeneman, Brenda Uyl-de Groot, Carin A. Aarts, Maureen J. B. van Akkooi, Alexander C. J. van den Berkmortel, Franchette W. P. J. van den Eertwegh, Alfons J. M. de Groot, Jan Willem B. Herbschleb, Karin H. van der Hoeven, Jacobus J. M. Hospers, Geke A. P. Kapiteijn, Ellen Piersma, Djura van Rijn, Rozemarijn S. Suijkerbuijk, Karijn P. M. ten Tije, Albert J. van der Veldt, Astrid A. M. Vreugdenhil, Gerard Wouters, Michel W. J. M. Haanen, John B. A. G. Franken, Margreet G. |
author_sort | Leeneman, Brenda |
collection | PubMed |
description | Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients who were registered between July 2012 and December 2018. Mean total/monthly costs per patient were reported for all patients, patients who did not receive systemic therapy, and patients who received systemic therapy. Furthermore, mean episode/monthly costs per line of therapy and drug were reported for patients who received systemic therapy. Mean total/monthly costs were € 89,240/€ 6809: € 7988/€ 2483 for patients who did not receive systemic therapy (n = 784) and € 105,078/€ 7652 for patients who received systemic therapy (n = 4022). Mean episode/monthly costs were the highest for nivolumab plus ipilimumab (€ 79,675/€ 16,976), ipilimumab monotherapy (€ 79,110/€ 17,252), and dabrafenib plus trametinib (€ 77,053/€ 12,015). Dacarbazine yielded the lowest mean episode/monthly costs (€ 6564/€ 2027). Our study showed that immunotherapeutic and targeted drugs had a large impact on real-world healthcare costs. As new drugs continue entering the treatment landscape for (metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh their costs. |
format | Online Article Text |
id | pubmed-7225943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72259432020-05-18 Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs Leeneman, Brenda Uyl-de Groot, Carin A. Aarts, Maureen J. B. van Akkooi, Alexander C. J. van den Berkmortel, Franchette W. P. J. van den Eertwegh, Alfons J. M. de Groot, Jan Willem B. Herbschleb, Karin H. van der Hoeven, Jacobus J. M. Hospers, Geke A. P. Kapiteijn, Ellen Piersma, Djura van Rijn, Rozemarijn S. Suijkerbuijk, Karijn P. M. ten Tije, Albert J. van der Veldt, Astrid A. M. Vreugdenhil, Gerard Wouters, Michel W. J. M. Haanen, John B. A. G. Franken, Margreet G. Cancers (Basel) Article Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients who were registered between July 2012 and December 2018. Mean total/monthly costs per patient were reported for all patients, patients who did not receive systemic therapy, and patients who received systemic therapy. Furthermore, mean episode/monthly costs per line of therapy and drug were reported for patients who received systemic therapy. Mean total/monthly costs were € 89,240/€ 6809: € 7988/€ 2483 for patients who did not receive systemic therapy (n = 784) and € 105,078/€ 7652 for patients who received systemic therapy (n = 4022). Mean episode/monthly costs were the highest for nivolumab plus ipilimumab (€ 79,675/€ 16,976), ipilimumab monotherapy (€ 79,110/€ 17,252), and dabrafenib plus trametinib (€ 77,053/€ 12,015). Dacarbazine yielded the lowest mean episode/monthly costs (€ 6564/€ 2027). Our study showed that immunotherapeutic and targeted drugs had a large impact on real-world healthcare costs. As new drugs continue entering the treatment landscape for (metastatic) melanoma, it remains crucial to monitor whether the benefits of these drugs outweigh their costs. MDPI 2020-04-18 /pmc/articles/PMC7225943/ /pubmed/32325748 http://dx.doi.org/10.3390/cancers12041003 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Leeneman, Brenda Uyl-de Groot, Carin A. Aarts, Maureen J. B. van Akkooi, Alexander C. J. van den Berkmortel, Franchette W. P. J. van den Eertwegh, Alfons J. M. de Groot, Jan Willem B. Herbschleb, Karin H. van der Hoeven, Jacobus J. M. Hospers, Geke A. P. Kapiteijn, Ellen Piersma, Djura van Rijn, Rozemarijn S. Suijkerbuijk, Karijn P. M. ten Tije, Albert J. van der Veldt, Astrid A. M. Vreugdenhil, Gerard Wouters, Michel W. J. M. Haanen, John B. A. G. Franken, Margreet G. Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs |
title | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs |
title_full | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs |
title_fullStr | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs |
title_full_unstemmed | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs |
title_short | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs |
title_sort | healthcare costs of metastatic cutaneous melanoma in the era of immunotherapeutic and targeted drugs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225943/ https://www.ncbi.nlm.nih.gov/pubmed/32325748 http://dx.doi.org/10.3390/cancers12041003 |
work_keys_str_mv | AT leenemanbrenda healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT uyldegrootcarina healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT aartsmaureenjb healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT vanakkooialexandercj healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT vandenberkmortelfranchettewpj healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT vandeneertweghalfonsjm healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT degrootjanwillemb healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT herbschlebkarinh healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT vanderhoevenjacobusjm healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT hospersgekeap healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT kapiteijnellen healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT piersmadjura healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT vanrijnrozemarijns healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT suijkerbuijkkarijnpm healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT tentijealbertj healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT vanderveldtastridam healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT vreugdenhilgerard healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT woutersmichelwjm healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT haanenjohnbag healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs AT frankenmargreetg healthcarecostsofmetastaticcutaneousmelanomaintheeraofimmunotherapeuticandtargeteddrugs |